AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

1/21/25 4:05:00 PM ET

Pharmaceuticals and Biotechnology

Health Care

Get the next $ABCL alert in real time by email

AbCellera (NASDAQ:ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250121134637/en/

Inquiries

Media: Tiffany Chiu; [email protected], +1(236)521-6774

Partnering: Murray McCutcheon, Ph.D.; [email protected], +1(604)559-9005

Investor Relations: Peter Ahn; [email protected], +1(778)729-9116

Get the next $ABCL alert in real time by email

Recent Analyst Ratings for

$ABCL

Date	Price Target	Rating	Analyst
8/20/2024		Buy → Hold	The Benchmark Company
2/22/2024	$9.00	Hold → Buy	The Benchmark Company
12/5/2023	$6.00	Overweight	KeyBanc Capital Markets
11/6/2023		Buy → Hold	The Benchmark Company
10/13/2023	$20.00	Overweight	Piper Sandler
2/28/2023		Outperform	Cowen
12/15/2022	$30.00	Buy	Goldman
11/16/2022	$29.00	Buy	Truist

More analyst ratings

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Chat with this insight

Recent Analyst Ratings for $ABCL

$ABCL SEC Filings

AbCellera Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

AbCellera Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

AbCellera Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$ABCL Leadership Updates

Live Leadership Updates

$ABCL Large Ownership Changes

This live feed shows all institutional transactions in real time.

$ABCL Financials

Live finance-specific insights

$ABCL Press Releases

Fastest customizable press release news feed in the world

AbCellera Announces Resignation of Board Member

DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer

AbCellera Announces Changes to Its Board of Directors

Amendment: SEC Form SC 13G/A filed by AbCellera Biologics Inc.

SEC Form SC 13G filed by AbCellera Biologics Inc.

SEC Form SC 13G/A filed by AbCellera Biologics Inc. (Amendment)

AbCellera Reports Q1 2025 Business Results

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Reports Full Year 2024 Business Results

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

$ABCL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

AbCellera Biologics downgraded by The Benchmark Company

AbCellera Biologics upgraded by The Benchmark Company with a new price target

KeyBanc Capital Markets initiated coverage on AbCellera Biologics with a new price target

$ABCL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Thermopylae Holdings Ltd. bought $742,243 worth of shares (343,631 units at $2.16), increasing direct ownership by 0.62% to 56,143,640 units (SEC Form 4)

Director Montalbano John S. bought $57,500 worth of shares (25,000 units at $2.30), increasing direct ownership by 17% to 171,000 units (SEC Form 4)

Director Montalbano John S. bought $140,568 worth of shares (60,000 units at $2.34), increasing direct ownership by 70% to 146,000 units (SEC Form 4)

$ABCL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Thermopylae Holdings Ltd. bought $742,243 worth of shares (343,631 units at $2.16), increasing direct ownership by 0.62% to 56,143,640 units (SEC Form 4)

Director Montalbano John S. bought $57,500 worth of shares (25,000 units at $2.30), increasing direct ownership by 17% to 171,000 units (SEC Form 4)

Director Montalbano John S. bought $140,568 worth of shares (60,000 units at $2.34), increasing direct ownership by 70% to 146,000 units (SEC Form 4)

Recent Analyst Ratings for
$ABCL

$ABCL
SEC Filings

$ABCL
Leadership Updates

$ABCL
Large Ownership Changes

$ABCL
Financials

$ABCL
Press Releases

$ABCL
Analyst Ratings

$ABCL
Insider Trading

$ABCL
Insider Purchases